India Pharma Outlook Team | Thursday, 30 October 2025
India has increased its trade protection actions by broadening an anti-dumping probe concerning the import of Ethambutol Hydrochloride, which is a major one of the six essential active pharmaceutical ingredient (API) of anti-TB (Tuberculosis) medicines originating in China and Thailand.
The Directorate General of Trade Remedies (DGTR) has published a list of registered interested parties suggesting the next stage of the investigation.
According to a PTI report, the investigation followed a petition filed by Lupin Ltd last month. Lupin Ltd is one of the Indian top pharmaceutical companies. It alleged that the imported product was dumped in the Indian market and that as a result, the domestic producers were suffering material injury.
In a statement, the DGTR named Wuhan Wuyao Pharmaceuticals Co. Ltd as one of the foreign producers whose operations are being examined. The preliminary findings pinpointed that there was evidence of price undercutting and resulting injury of Indian manufacturers.
Also Read: Arpit Bhatia Says EU GMP Fuels Laborate Pharma Growth
The period under examination will be from April 2024 to March 2025 and the authority may impose anti-dumping charges if it finds the accusations to be true.
India is gradually taking steps to protect its local industries from unfair trade practices. The DGTR has been very active as evidenced by the fact that in September it made 15 final decisions on dumping cases in different sectors such as steel, glass fiber, solar cells, and chemicals.
It also started 13 new anti-dumping and countervailing cases, mostly related to imports from China and South Korea, to implement the government's overall plan to ensure fair competition and increase the domestic manufacturing sector’s resilience.
.jpg)
